The ability of the CTLs to recognize the processed peptides derived from the cellular genes, such as those encoding MART-1 or tyrosinase in melanoma, led to the recognition that protective immune responses are often directed towards tumor-associated, rather than tumor-specific, antigens [28,29]. The gene discussed is MLANA; the disease is melanoma.